Press releases
- Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
- Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
- Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
- Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
- Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
- Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
- Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
- Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
- Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
- Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
More ▼
Key statistics
On Wednesday, Arrowhead Pharmaceuticals Inc (A2RR34:SAO) closed at 18.18, 28.12% above the 52 week low of 14.19 set on May 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 18.18 |
---|---|
High | 18.18 |
Low | 18.18 |
Bid | 8.55 |
Offer | -- |
Previous close | 18.18 |
Average volume | 1.14k |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Jun 26 2024 10:29 BST.
More ▼